DNA damage activates nuclear Abl tyrosine kinase to stimulate intrinsic apoptosis in cancer cell lines and mouse embryonic stem cells. To examine the in vivo function of nuclear Abl in apoptosis, we generated Abl-lNLS (l, mutated in nuclear localization signals) mice. We show here that cisplatin-induced apoptosis is defective in the renal proximal tubule cells (RPTC) from the Abl l/l mice. When injected with cisplatin, we found similar levels of platinum in the Abl þ / þ and the Abl l/l kidneys, as well as similar initial inductions of p53 and PUMAa expression. However, the accumulation of p53 and PUMAa could not be sustained in the Abl l/l kidneys, leading to reductions in renal apoptosis and tubule damage. Co-treatment of cisplatin with the Abl kinase inhibitor, imatinib, reduced the accumulation of p53 and PUMAa in the Abl þ / þ but not in the Abl l/l kidneys. The residual apoptosis in the Abl l/l mice was not further reduced in the Abl l/l ; p53 À / À double-mutant mice, suggesting that nuclear Abl and p53 are epistatic to each other in this apoptosis response. Although apoptosis and tubule damage were reduced, cisplatin-induced increases in phospho-Stat-1 and blood urea nitrogen were similar between the Abl þ / þ and the Abl l/l kidneys, indicating that RPTC apoptosis is not the only factor in cisplatin-induced nephrotoxicity. These results provide in vivo evidence for the pro-apoptotic function of Abl, and show that its nuclear localization and tyrosine kinase activity are both required for the sustained expression of p53 and PUMAa in cisplatin-induced renal apoptosis. The ubiquitously expressed Abl tyrosine kinase contains three nuclear localization signals (NLS), a nuclear export signal (NES), 1,2 and undergoes nucleocytoplasmic shuttling in response to cell adhesion or DNA damage.
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. In embryonic stem (ES) cells, the Abl-mNLS mutation blocked nuclear import and reduced Bax activation by DNA damage. 7 We have since achieved germline transmission of the Abl-mNLS allele and show here that the Abl m/m mice are protected from cisplatin-induced renal apoptosis.
We chose cisplatin-induced nephrotoxicity as an experimental model because it is a toxic side effect in platinumbased therapies of ovarian, testicular, and other cancers. 16 The epithelial cells of the renal proximal tubules (RPTC) are particularly sensitive to cisplatin due to an active uptake mechanism, and these cells undergo cisplatin-induced apoptosis. 17, 18 Previous studies using mouse genetic models have identified a number of mechanisms underlying cisplatininduced nephrotoxicity, including intrinsic apoptosis, mitochondrial reactive oxygen species (ROS) production, and inflammation. [19] [20] [21] In this study, we provide evidence that the nuclear import and the tyrosine kinase activity of Abl are also required for cisplatin to induce RPTC apoptosis in the mice.
Results
RPTCs from Abl l/l mice are resistant to cisplatin-induced apoptosis. We succeeded in germline transmission of the Abl-mNLS allele (Supplementary Figure s1) and found that the Abl m/m mice are healthy and fertile (Table 1) . In mice, the knockout of the Abl-related gene (Arg/Abl2) alone is well tolerated, but the combined loss of Abl and Arg caused early embryonic lethality. 22 We found that homozygous mutations of Abl-mNLS and Arg caused late embryonic lethality due to brain developmental defects, indicating that Arg is required for the proper development of the Abl m/m mice (not shown). Together, these breeding results show that nuclear Abl is not essential to mouse development, and that defect in the cytoplasmic Abl function causes neonatal lethality. In the Abl m/m mouse embryo fibroblasts (MEFs), only cytoplasmic Abl was detected (Figure 1a ). Treatment with leptomycin B (LMB), which inhibits nuclear export, 2, 7 caused Abl nuclear accumulation in the Abl þ / þ but not in the Abl m/m MEFs ( Figure 1a ). We also prepared primary cultures of RPTC ( Figure 1b ) and confirmed their identity by the expression of Megalin (Lrp2, an endocytosis receptor for protein reabsorption) 23 ( Figure 1c ). In the Abl þ / þ RPTC, Abl was diffusively localized in the cytoplasm and the nucleus, whereas only cytoplasmic Abl was detected in the Abl Cisplatin-induced p53 response is blunted in Abl l/l kidneys. We then compared the in vivo apoptotic response in the Abl þ / þ and the Abl m/m kidneys in a model of cisplatininduced nephrotoxicity. 24 We observed similar platinum levels in the Abl þ / þ and the Abl m/m kidneys at 24 and 48 h (Figure 2a) , showing that the renal uptake, accumulation, and removal of platinum were not affected by the Abl-mNLS mutation. In both the Abl þ / þ and the Abl m/m mice, cisplatin injection induced nuclear p53 expression in the kidney tissues (Figures 2b and c) . Nuclear p53 signal was not detectable in cisplatin-treated p53 À / À mice, demonstrating specificity of this immunohistochemistry (IHC) assay (Figure 2b (Figure 2d , left). However, co-injection with imatinib reduced the p53 levels in the Abl þ / þ but not in the Abl m/m kidneys at the 48-h time point (Figure 2d , right). We found that the p53 mRNA was also upregulated in the Abl þ / þ and Abl m/m kidneys after cisplatin injection ( Figure 2e ). The induction of Tp53 transcription could be due to the activation of protein kinase C-delta (PKCd). 21, 25 Interestingly, the Tp53 mRNA levels were also reduced at the 48-h time point in the Abl m/m kidneys ( Figure 2e ). Taken together, these results show that the induction of p53 expression by cisplatin is not affected by the Abl-mNLS mutation. However, the continued accumulation of p53 in cisplatin-damaged renal tissues required the nuclear import and the kinase activity of Abl.
An important regulator of the p53 protein levels is the Mdm2 E3-ubiquitin ligase, which suppresses the accumulation of p53 at steady state. 26 In response to DNA damage, a number of pathways are activated to disrupt the p53-Mdm2 interaction, leading to the accumulation of p53. 27 The activated p53 then stimulates the transcription of Mdm2 to establish a negative feedback loop that controls the extent and duration of the p53 response. 28 We found similar basal levels of Mdm2 mRNA in the untreated Abl þ / þ and the Abl m/m kidneys, and similar increases after cisplatin injection (Figure 2e ). This result showed that nuclear Abl was not required for cisplatin to stimulate Mdm2 transcription. In total kidney extracts from the Abl þ / þ mice, the Mdm2 protein levels were elevated after cisplatin injection (Figure 2d, Supplementary Figure s2c) . However, in the Abl m/m kidneys, the basal levels of Mdm2 protein were higher and cisplatin injection did not increase the Mdm2 protein despite upregulation of its mRNA (Figure 2d Figure s2c) . A previous study showed that Mdm2-mediated p53 degradation could be inhibited by the ectopic expression of Abl or a kinase-defective Abl. 29 Furthermore, it was shown that Abl, but not Abl-mNLS, co-immunoprecipitated with Mdm2. 30 Those results suggest that the Abl-Mdm2 interaction would be lost in the Abl m/m mice, and this defect could have accounted for the blunted accumulation of the p53 protein in the Abl m/m kidneys. It has Figures 3a and b) . The reduced TUNEL staining correlated with the reduced expression of p53 and PUMAa in the Abl m/m kidneys at the 48-h time point (Figure 2 ). At 72 h after cisplatin injection, TUNEL staining became unreliable due to the accumulation of protein casts in the renal tissues (Figure 3c ). We therefore assessed the proximal tubule (PT) damage by PAS (Periodic Acid Schiff) staining, which reacts with the brush borders of PT epithelial cells and the glycoprotein aggregates (casts) that accumulate in the damaged PT. 32 In the Abl þ / þ renal tissues, PAS-positive casts (*) and droplets (arrows) were readily detected at 72 h ( Figures 3c and d) ; by comparison, these PAS-positive features were significantly lower in the Abl m/m tissues (Figures 3c and d) . Imatinib treatment alone did not alter the PAS staining or the PT morphology in renal tissues (Figures 3c and d) . However, co-injection with cisplatin plus imatinib significantly reduced the number of PAS-positive protein casts in the Abl þ / þ but not in the Abl m/m kidneys (Figures 3c and d) . These results showed that the reduced apoptosis (48 h) correlated with reduced PT damage (72 h) in the Abl m/m kidneys. Therefore, cisplatin-induced renal apoptosis and PT damage require the nuclear import and the tyrosine kinase activity of Abl.
No further reduction of renal apoptosis by combining Abl-lNLS with p53-null mutations. It has been demonstrated that cisplatin-induced renal apoptosis requires p53. 33 We therefore compared the apoptotic response in the Abl m/m and the p53 À / À kidneys. To compare littermates, we first generated the Abl þ /m ; p53 þ / À mice. Intercrossing of these compound heterozygotes generated p53 À / À ; Abl m/m male, but not female, pups at the expected Mendelian frequency (Table 2) , indicating female-specific developmental defects of the double mutants. Interestingly, we found that the renal apoptotic response to cisplatin was reduced to similar low levels in the Abl m/m and the p53 À / À single-mutant mice (Figure 4c ). These lower levels of TUNEL staining were not further reduced in the Abl (Figures 4a and c) . We also measured PT damage by PAS staining at 72 h and found that the levels of cast-positive tubules were similarly reduced in each of the single-and the double-mutant kidneys (Figures 4b and d) . Moreover, there were no significant differences among the Abl
, and the Abl m/m ; p53 À / À kidneys in cisplatin-induced PT damage (Figures 4b and d) . These results show that the nuclear Abl is as important as p53 in cisplatin-induced renal apoptosis and tubule damage, and that the nuclear Abl and p53 are epistatic to each other in this apoptotic response.
We also examined the levels of p53, PUMAa, and cleaved caspase-3 (DC3) in total kidney extracts from the single and the double mutants at the 72-h time point (Figure 4e,  Supplementary Figures s3a-c) . In the Abl m/m ; p53
kidneys, we observed variable, but consistent, reductions in p53, PUMAa, and DC3. In the Abl þ / þ ; p53 À / À kidneys, we found reduced DC3 in kidneys with high levels of PUMAa in some mice (Figure 4e, Supplementary Figures s3b and c) . Although PUMA was identified as a target gene of p53, 31 the transcription of PUMA can be stimulated by other factors including p63, p73, NF-kB, FOXO, and SMAD4. [34] [35] [36] [37] [38] Previous studies have shown that cisplatin activates the Abl tyrosine kinase to stimulate p63 and p73. [9] [10] [11] [12] The wild-type level of PUMAa expression in some of the Abl þ / þ ; p53 À / À kidneys could, therefore, be driven by the Abl-p63 or the Abl-p73 pathways. Previous studies have also shown that the cytoplasmic p53 can stimulate mitochondrial outer membrane permeability transition. [39] [40] [41] The loss of this cytoplasmic p53 function might explain the reduced DC3 formation in those Abl þ / þ ; p53 À / À kidneys that expressed wild-type levels of PUMAa. In other words, both the PUMAa and the cytoplasmic p53 are required for cisplatin to induce caspase-3 cleavage in the mouse kidneys. [39] [40] [41] In the kidneys of the Abl Reduction in renal apoptosis did not ameliorate nephrotoxicity. In patients, nephrotoxicity is routinely assessed by blood urea nitrogen (BUN) and serum creatinine, which are delayed biomarkers for kidney injury, as these levels reflect the glomerular filtration rate. 43, 44 Consistent with it being a delayed marker, we detected significant increases in the BUN levels only at the 72-h time point (Supplementary Figure s4a) . We then measured the BUN levels across the nine genotypes generated by crossing the Abl þ /m ; p53 þ / À mice, and found that BUN increases in all mice (Figure 5a ). The variations in the BUN increases were statistically insignificant (Figure 5a ). The serum-creatinine levels were also similarly increased between the Abl þ / þ and the Abl m/m mice (Supplementary Figure s4b) . At a lower dose of cisplatin, the increases in BUN were again found to be similar between the Abl þ / þ and the Abl m/m mice ( Supplementary  Figure s4c) . These results suggest that the kidneys were still injured in the Abl m/m mice. We therefore measured the levels of Kim-1 (Kidney Injury Molecule-1) RNA, which is consistently upregulated in different models of kidney injury 44, 45 and found similar levels of Kim-1 induction by cisplatin in the Abl þ / þ and Abl m/m kidneys (Supplementary Figure s4d) . A recent study has shown that cisplatin activates Stat-1 phosphorylation in the cochlea of rats and that administration of Stat-1-siRNA blocked cisplatin-induced hearing loss measured by the auditory brainstem response threshold. 46 The phosphorylation of Stat-1 leads to activation of downstream targets such as iNos and Cox-2, which induce inflammation to cause hair cell damage. 46 We found that Stat-1 was expressed at comparable levels in the Abl 
Discussion
The study of the Abl-mNLS mice has provided the first in vivo evidence for the pro-apoptotic function of Abl, and shown that nuclear Abl is as important as p53 in cisplatin-induced renal apoptosis. Furthermore, this in vivo study has generated new insights on the nuclear Abl tyrosine kinase function in apoptosis. First, our previous study of the Abl m/m ES cells 7 and this study of the Abl m/m kidneys have shown that the induction of p53 expression by cisplatin does not require Abl nuclear import. Instead, we found that nuclear Abl is required for the continued accumulation of p53. Second, the study of the Abl m/m kidneys has indicated an unexpected role for nuclear Abl in the regulation of Mdm2 protein expression. Third, we have found that nuclear Abl is required for the sustained expression of PUMAa protein in cisplatin-induced apoptosis. The nuclear Abl-dependent p53 accumulation is consistent with the previous findings that Abl interacts with Mdm2 to block p53 degradation 29 and that the Abl-mNLS mutant protein is defective in binding Mdm2. 30 Besides the p53 protein, we found that its mRNA was also upregulated by cisplatin in the kidneys. A previous study has shown that DNA damage upregulates Tp53 transcription through PKCd, 25 which is activated by cisplatin in the mouse 21 Several studies have suggested an interdependent activation of Abl and PCKd by ROS. 47, 48 Although the initial upregulation of the Tp53 mRNA was not affected by Abl-mNLS, its levels were reduced at a later time, indicating that the PKCd activity might be lowered in the Abl m/m kidneys. An important pro-apoptotic target gene of p53 is PUMAa, 31, 49 which is a BH3-only protein that sequesters the anti-apoptotic Bcl2-family members to stimulate Bax and Bak-dependent mitochondrial outer membrane permeabilization (MOMP). [50] [51] [52] [53] [54] We show here that nuclear Abl is not required for cisplatin to induce PUMAa RNA. However, nuclear Abl is required for the sustained expression of the PUMAa protein. This finding is completely unexpected and indicates a novel function for nuclear Abl in the regulation of PUMAa translation or protein stability. Interestingly, we found that cisplatin could still induce PUMAa expression in the Abl þ / þ ; p53 À / À kidneys, but PUMAa expression was lost in the kidneys of the double-mutant mice (Abl m/m ;p53 À / À ). The upregulation of PUMAa in the Abl þ / þ ; p53 À / À mice is likely to be mediated by p63 and/or p73, as previous studies have established a redundant role of these three transcription factors in PUMAa expression. [34] [35] [36] [37] [38] This study also shows that p53 and nuclear Abl-dependent apoptotic response is not the only factor in cisplatin-induced nephrotoxicity. The pathophysiology of acute kidney injury involves epithelial cell death, interstitial inflammation, small vessel obstruction, and local ischemia. 44 Other than apoptosis, cisplatin also induces oxidative stress, necrosis, autophagy, and inflammation in the renal tissues. 20, 55 In the Abl m/m mice, injection with cisplatin stimulated the expression of Kim-1, which encodes a transmembrane glycoprotein that is upregulated in response to kidney injury caused by many different agents. 44, 45 Furthermore, we found that cisplatin induced the phosphorylation of Stat-1 in the kidneys of the Abl þ / þ and Abl m/m mice. As Stat-1 has been shown to be required for cisplatin to cause ototoxicity (hearing loss) in the rats, 46 the activation of Stat-1 could have contributed to cisplatin-induced nephrotoxicity in the Abl m/m mice. Therefore, a concerted strategy that targets the nuclear Abl and the Stat-1 pathways may be required to ameliorate nephrotoxicity associated with platinum-based cancer therapy. Genotyping primers. The Abl genotypes were determined from tail DNA by PCR using the following primers: forward, 5 0 -TGTGTCGACCCTCGGTGTCAT-3 0 , reverse, 5 0 -GATGGCCTCGAGAAAACTTCA-3 0 (Supplementary Figure s1) . Genotyping of the p53-null allele was according to Jacks et al.
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Mice. Breeding, handling, and experimentation with mice were according to protocols approved by The Institutional Animal Care and Use Committees of University of California at San Diego. Embryonic stem cells with one AblmNLS (m) allele containing the neomycin-resistant gene (neo) cassette flanked by loxp sites were previously described. 7 Following germline transmission of this Ablm-loxPNeo-loxP allele, female were bred with male protamine-Cre-transgenic mice to remove the Neo cassette. The Abl þ /m mice were then bred with the p53 þ / À mice (from the Jax lab, Bar Harbor, ME, USA) to generate a breeding colony of Abl
Cisplatin treatment. To induce acute renal failure, mice (8-10 weeks of age) were given a single intraperitoneal injection of cisplatin at 20 mg/kg body weight (b.w.). With imatinib treatment (50 mg/kg b.w.), mice were injected intraperitoneally with 2 mg/ml imatinib mesylate solution in PBS. Imatinib was given 2 h prior to cisplatin and every 12 h thereafter until the end of treatment. At this dose, the plasma concentration of imatinib is at 8-10 mM at 2 h after injection and decays thereafter, but remains above 1 mM for 8 h. 57 Mice were euthanized at the indicated time points by carbon dioxide asphyxiation; tissues were retrieved and blood collected by cardiac puncture.
Preparation of mouse RPTCs. Mouse RPTC were prepared as described. 58 Briefly, mouse renal cortices were minced in ice-cold dissection solution (10 mM glucose, 5 mM glycine, 1 mM alanine, 15 mM HEPES, pH 7.4, 150 mM NaCl with osmolality at 325 osmol/kg H 2 O), digested for 30 min at 37 1C with type-2 collagenase (0.1% w/v in DS) and filtered through 70 mm mesh sieves. The PT fragments that did not pass through the 70-mm sieves were resuspended by flushing the sieve in the reverse direction with warm DS (37 1C) containing 1% (w/v) bovine serum albumin (BSA). The PT fragments were then cultured at 37 1C with 5% CO 2 in medium containing 1 : 1 DMEM/F12, 1% FCS, 15 mM HEPES, 2 mM L-glutamine, 50 nM hydrocortisone, 5 mg/ml each of insulin and transferrin, 50 nM selenium, 0.55 mM sodium pyruvate, nonessential amino acids, penicillin 100 IU/ml, and streptomycin 100 mg/ml, pH 7.4. The medium was changed every 2 days. For immunofluorescence staining, RPTC were directly seeded onto acidwashed and poly-L-lysine-coated coverslips. The percentage of RPTC in these primary cultures was 480%, as determined by immunofluorescence staining for the RPTC marker megalin.
Immunofluorescence. Cells were fixed with 4% paraformaldehyde for 20 min, permeabilized with 0.3% Triton X-100 for 20 min, and blocked with 5% BSA for 30 min. The coverslips were incubated with anti-Abl (8E9) antibody (30 mg/ml) for 2 h, followed by ALEXA fluor-488 (Invitrogen)-chicken anti-mouse (1 : 500) for an hour at 37 1C. Nuclei were stained with DAPI (4 0 ,6-diamidino-2-phenylindole dihydrochloride) (Sigma Aldrich).
Immunoblotting. Mouse kidneys were homogenized on ice in RIPA buffer (25 mM Tris-HCl pH 7.4, 1 mM EDTA, 0.1% SDS, 150 mM NaCl, 1% NP-40, 1% sodium deoxycholate, 1 mM phenylmethylsulfonyl fluoride, and protease inhibitor cocktail). The lysates were sonicated and centrifuged at 12 000 r.p.m. for 10 min. The supernatant was quantified using Bio-Rad Lowry protein assay reagent, and 30-50 mg lysates were loaded per lane of SDS polyacrylamide gels. Western blotting was performed by standard protocols.
RNA analysis. Total RNA was extracted from frozen kidneys using RNA extraction kit (Qiagen, Germantown, MD, USA) and converted to cDNA using ABI kit, following the manufacturer's protocol (Life Technologies, Carlsbad, CA, USA). The primer sets used were as follows: GAPDH ( Histology and IHC. For assessment of kidney tissue injury, 5-mm sections were stained with PAS. Tubular protein casts were counted in at least eight random fields in the PAS-stained sections. For p53 and PUMAa IHC, sections were deparaffinized, rehydrated, and antigen retrieval achieved by heating in Retrievagen A (pH 6.0) from BD biosciences, at 95 1C for 15 min. The sections were allowed to cool down, and immunostaining was performed using Dako DAB-IHC kit (Dako Technologies, Carpinteria, CA, USA), following the manufacturer's protocol to stain the antigen brown. Hematoxylin was used to counterstain the nuclei blue.
BUN and serum-creatinine measurement. Nephrotoxicity was assessed by BUN and serum creatinine levels using Quantichrom DI-UR500 urea assay kit and Quantichrom CT500 creatinine assay kit, respectively (Bioassay Systems, Hayward, CA, USA).
TUNEL assay. TUNEL was performed on tissue sections using Trevigen TACS.XL-Blue in situ apoptosis detection kit (Trevigen, Gaithersburg, MD, USA). Nuclei were counterstained with nuclear fast red. Sections were photographed ( Â 200), and apoptotic nuclei and apoptotic bodies in at least eight representative fields were counted per mouse. TUNEL labeling was performed on RPTC cells using Takara In situ Apoptosis Detection Kit. RPTC nuclei were stained with DAPI, and TUNEL-positive cells were counted in six fields out of a total of around 200 nuclei.
Measurement of tissue platinum. Whole kidneys were blotted dry, weighed, finely minced, transferred into conical tubes containing 215 ml of concentrated nitric acid, and digested overnight at 60 1C. The digested tissues were diluted with 3 ml of buffer containing 0.1% Triton X-100, 1.4% v/v concentrated nitric acid and 1 ppb Indium. The digested samples were subjected to inductively coupled plasma/mass spectroscopy (ICP-MS) to determine the platinum content.
Statistical methods. For statistical analysis, Prism 5.0 software (GraphPad Software, San Diego, CA, USA) was used. The statistical significance, when only two groups were compared, was assessed using t-test. Two-way ANOVA with Bonferroni post-test analysis was used to compare the effects of the different treatments (cisplatin versus cisplatin þ IM) on the two Abl genotypes.
